The phase II CHRONOS trial in metastatic colorectal cancer provided proof of principle that cfDNA could guide therapeutic rechallenge with panitumumab (40), and the DYNAMIC trial will use ctDNA to direct AT with BRAF and MEK inhibitors in advanced malignant melanoma (41). This evidence concerns the gene BRAF and melanoma.